What is Zacks Research’s Estimate for APLS FY2024 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at Zacks Research lowered their FY2024 earnings per share estimates for Apellis Pharmaceuticals in a report released on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.78) for the year, down from their prior estimate of ($1.55). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.71) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.40) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.55) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period last year, the company posted ($1.17) EPS. The firm’s revenue was up 78.3% compared to the same quarter last year.

Several other research analysts also recently issued reports on APLS. Scotiabank lowered their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 6th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target on the stock. Finally, HC Wainwright dropped their price objective on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Trading Up 4.6 %

Shares of APLS stock opened at $34.14 on Thursday. Apellis Pharmaceuticals has a twelve month low of $24.34 and a twelve month high of $73.80. The stock’s fifty day simple moving average is $28.74 and its 200 day simple moving average is $35.41. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $4.25 billion, a P/E ratio of -16.82 and a beta of 0.87.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. This represents a 27.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Braidwell LP boosted its stake in Apellis Pharmaceuticals by 410.8% during the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after buying an additional 2,513,383 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares during the last quarter. Fiera Capital Corp grew its holdings in shares of Apellis Pharmaceuticals by 47.7% during the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after purchasing an additional 452,753 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth approximately $6,226,000. Finally, AQR Capital Management LLC raised its stake in Apellis Pharmaceuticals by 337.3% in the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).